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Abstract Over the last 10 years, the diagnosis small fiber
neuropathy (SFN) has gained recognition worldwide.
Patients often suffer from severe neuropathic pain that may
be difficult to treat. A substantial subset of patients with
SFN is aged 65 years or older, and these patients often
exhibit comorbidities and usage of multiple drugs, making
neuropathic pain treatment more challenging. In this
review, we highlight relevant pathophysiological aspects
and discuss currently used therapeutic strategies for neuro-
pathic pain. Possible pitfalls in neuropathic pain treatment
in the elderly will be underlined.
Key Points
Treatment of neuropathic pain due to small fiber
neuropathy may be challenging.
Comorbidity and polypharmacy are more frequent in
the elderly, making treatment even more
challenging.
Especially in the elderly, topical treatment may be
considered as first-line treatment, whereas tricyclic
antidepressants are best avoided.
1 Introduction
Small fiber neuropathy (SFN) is a peripheral neuropathy in
which predominantly the unmyelinated C-fibers and thinly
myelinated Ad-fibers are affected [1]. The diagnosis is
based on clinical symptoms, reduced intra-epidermal nerve
fiber density in skin biopsy, and/or abnormal temperature
threshold tests [2–4], and no large nerve fiber involvement
at physical examination or nerve conduction tests. The
prevalence is at least 53 cases per 100,000 inhabitants, and
the rates are higher in elderly patients [5]. Many conditions
have been associated with SFN, such as diabetes mellitus,
hyperlipidemia, amyloidosis, Fabry syndrome, celiac dis-
ease, sarcoidosis and other systemic illnesses, human
immunodeficiency virus (HIV) infection, and hereditary
sensory and autonomic neuropathies [3]. Recently, also
pathogenic mutations in sodium channels (NaV1.7, NaV1.8
and NaV1.9) were reported in patients with painful neu-
ropathy [6]. Despite a comprehensive work-up of patients
with SFN, in a substantial proportion (ranging from 24 to
93 % in different series), no underlying cause can be
identified [3].
SFN patients often suffer from devastating pain, and
have a severely reduced quality of life [7]. In addition to
the typical SFN-related complaints (neuropathic pain and
autonomic symptoms such as dry mouth, dry eyes, mic-
turation problems or bowel dysfunction), anxiety, depres-
sion, sleeping problems and fatigue may also influence
quality-of-life expectations [8–10]. Pain severity is asso-
ciated with a high use of medication, frequent physician
consultations and substantial health care costs [10].
For the symptomatic treatment of neuropathic pain in
SFN, mostly general guidelines are used [11–15]. Phar-
macological treatment options mainly are antidepressants
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[16], anticonvulsants [17] and opioids [18], with generally
disappointing results [14].
2 Pathways in Neuropathic Pain
Understanding pathways and mechanisms involved in
the development of neuropathic pain is important to
define possible therapeutic targets. Pain is defined as an
unpleasant sensory and emotional experience associated
with actual or potential tissue damage [19]. As the
definition suggests, pain is a subjective phenomenon,
and is difficult to catch in an objective outcome mea-
sure [20–23]. In humans, pain represents a final inte-
grative package, consisting of neurophysiological
processes as well as contextual, psychological, and
sociocultural factors.
Neuropathic pain is caused by a lesion or disease that
affects the somatosensory nervous system [19]. The thinly
myelinated Ad-fibers and unmyelinated C-fibers, predom-
inantly involved in SFN [1–3], arise in the skin where they
serve for the detection of cold, heat and, as nociceptors,
detection of painful stimuli [24–26]. In addition, they fulfill
an efferent function as part of the peripheral autonomic
nervous system [3, 27]. Generally, nociceptors are elec-
trically silent; after activation by noxious stimuli, an action
potential is initiated and transported via peripheral axons to
the cell bodies located in the trigeminal ganglia and in the
dorsal root ganglia alongside the spinal column and
medulla oblongata [6]. Via central axons, the signal is
transmitted onward to synapse on second-order neurons in
the central nervous system [24, 26]. Voltage-gated sodium,
potassium and calcium channels, transient receptor poten-
tial channels and acid-sensing ion channels all contribute to
the regulation of nociceptor excitability [24, 26, 28–30].
Recently, painful peripheral neuropathy has been linked to
three different types of voltage-gated sodium channel
(VGSC) mutations [6, 31–34].
Animal models and human studies have shown that
nerve damage, such as in painful peripheral neuropathy,
can result in pathological sensitization and ectopic impulse
generation in primary afferent nociceptors with subsequent
secondary changes in central processing [35]. Central
sensitization is largely mediated by the N-methyl-D-aspar-
tate (NMDA) receptor [36]. Activation of descending
pathways [spinal norepinephrine pathway and the
descending spinal serotonergic (5-HT) pathway] in the
periaqueductal gray-rostral ventromedial medulla oblon-
gata may also reduce pain transmission [37]. However, the
system may also facilitate pain transmission, thereby con-
tributing to chronic pain states [38–40].
3 Small Fiber Neuropathy in the Elderly
A substantial number of patients with SFN are 65 years or
older. In our cohort of 598 patients diagnosed with SFN,
diagnosed according to international criteria, at the Maas-
tricht University Medical Center [2, 3], 19 % were
65 years or older (n = 117). Most of these elderly patients
had several comorbidities at first presentation (Fig. 1a).
Only 11 % (n = 13) had no comorbidity (compared with
46 % in patients\65 years; V2 test, p\ 0.001). The most
frequent concomitant disorders were hypertension (60 %),
cardiovascular disease (44 %), immune-mediated diseases
(20 %), malignancy (16 %) and diabetes mellitus (9 %).
As a consequence, most patients used several drugs, on
average four (Fig. 1b). Only 6 % did not use any medi-
cation (compared with 26 % in patients\65 years; V2 test,
p\ 0.001).
The most frequently prescribed pain drugs in this group
of elderly patients were anticonvulsants (pregabalin,
Fig. 1 Comorbidities and use of drugs in the elderly. a Number of
comorbidities at initial presentation. b Number of drugs used at initial
presentation in patients with SFN aged 65 years or older (n = 117).
Concomitant disorders were hypertension (60 %), cardiovascular
disease (44 %), immune-mediated diseases (20 %), malignancy
(16 %) and diabetes mellitus (9 %). SFN small fiber neuropathy
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gabapentin, carbamazepine; 16 %), antidepressants
(amitriptyline, duloxetine, nortriptyline, venlafaxine;
14 %), opioids (weak and strong opioids; 14 %),
cyclooxygenase (COX) inhibitors (11 %) and acet-
aminophen (12 %).
The presence of comorbidity, polypharmacy and phys-
iological changes (e.g., increased body fat, reduced muscle
mass, reduction in body’s fluid balance, decrease in renal
and hepatic function) in older people increases the risk of
side effects and poses a challenge in symptomatic drug
treatment of neuropathic pain [41, 42].
4 Pharmacological Management of Neuropathic
Pain
Several therapeutic strategies are commonly used for the
treatment of neuropathic pain. Most pharmacological
treatment regimens exist in three groups: antidepressants,
anticonvulsants and opioids. However, less than 50 % of
patients achieve 50 % of pain relief with currently avail-
able drugs [12, 14]. Most of the available analgesics act at
different levels (e.g., sodium channels, noradrenergic sys-
tem, opioidergic system) and are prescribed without any
selection in terms of pathogenesis and etiology. Unfortu-
nately, none of the new drugs have proven to be more
effective than amitriptyline [12], an old antidepressant.
Additional treatment strategies are topical treatments, such
as capsaicin and lidocaine [14, 41], and transcutaneous
electrical nerve stimulation (TENS) [43].
4.1 Antidepressants
Since the 1960s, antidepressants have been used for pain
relief [44] and, nowadays, are mainly used for neuropathic
pain treatment. Tricyclic antidepressants (TCAs) and
serotonin-noradrenalin reuptake inhibitors (SNRIs) are
generally considered first-line treatments for neuropathic
pain [12, 14, 15].
4.1.1 Tricyclic Antidepressants
TCAs were initially synthesized as antipsychotic drugs, but
appeared to have an antidepressive trait [45, 46]. They are
widely used for neuropathic pain and have a number needed
to treat (NNT) of 3.6 [14]. TCAs are also known as dirty
drugs because of their actions on multiple neurotransmitter
receptors; they block reuptake of norepinephrine and
VGSCs, and are antagonists of H1-histaminic, muscarinic
cholinergic and a1-adrenergic receptors. Some TCAs inhibit
serotonin reuptake or are antagonists of serotonin 2A and 2C
receptors [47–53]. Other presumed effects are anti-inflam-
matory, increasing and decreasing cytokine production, and
potentiation of opioid analgesia [54–56]. TCAs may
improve sleep disturbances and, in higher doses, have an
antidepressive effect. The choice of a specific TCA is often
influenced by the side-effect profile. Secondary amine TCAs
(nortriptyline and desipramine) are preferred because they
are better tolerated than tertiary amine TCAs (amitriptyline
and imipramine) with comparable analgesic efficacy [15, 57,
58].
4.1.2 Serotonin-Noradrenalin Reuptake Inhibitors
As their name already suggests, SNRIs have a dual mono-
amine mechanism that should lead to better efficacy; how-
ever, for neuropathic pain, SNRIs have an NNT of 6.4 [14].
SNRIs indirectly also lead to an increase of dopamine in the
prefrontal cortex by blocking the norepinephrine trans-
porters, which may modulate pain [59, 60]. Venlafaxine and
duloxetine are well studied drugs for neuropathic pain [14].
Duloxetine has a lower incidence of side effects than ven-
lafaxine (such as hypertension, nausea and sexual dysfunc-
tion) [15, 61]. Precautions are needed in liver dysfunction,
severe kidney dysfunction, uncontrolled hypertension, and
with venlafaxine in significant cardiac disease. Simultaneous
use of other antidepressants and tramadol should be avoided.
4.1.3 Antidepressants and the Elderly
Age-associated morbidity can complicate treatment with
antidepressants. Antidepressants are metabolized more
slowly in the elderly, which can lead to a higher plasma drug
level. The American Geriatrics Society (AGS) strongly
recommends that TCAs should be avoided in older adults,
because of the risk of adverse events, such as cardiac
arrhythmia, somnolence, hypotension with increased risk of
falls and injury, cognitive impairment, and anticholinergic
side effects [62]. TCAs should certainly be dosed below
75 mg/day in adults aged greater than 65 years [14].
4.2 Anticonvulsants
Anticonvulsant drugs have been used since the 1960s for
pain management. They exhibit different mechanisms of
action. Gabapentin and pregabalin are considered first-line
treatment for neuropathic pain [12, 14, 15].
4.2.1 Gabapentin and Pregabalin
Gabapentin was initially designed in 1994 as an analog of
GABA (as an antiepileptic drug), which could penetrate the
blood–brain-barrier. In 1996, it became clear that gaba-
pentin had a therapeutic effect on pain. Pregabalin, a
chemically related amino-acid drug, was developed a few
years later.
Management of Neuropathic Pain in SFN in the Elderly 613
Though gabapentin initially was assumed to have a
GABA-mimetic effect, it turned out that gabapentin does
not interact with GABA-A or -B receptors and does not
influence GABA uptake [63]. Gabapentin and pregabalin
both bind to voltage-gated a2d-calcium channel of N type
and P/Q type in the dorsal horn, but also on the level of the
thalamus, periaqueductal gray and cortex [64]. These
presynaptic voltage-sensitive calcium channels are
involved in regulation of neurotransmitter release by firing
synaptic vesicles into the synapse. Binding gabapentin or
pregabalin blocks calcium influx and influences the release
of presynaptic neurotransmitters, such as GABA, gluta-
mate, acetylcholine, substance P and monoamines [65–68].
Gabapentin has an NNT of 7.2 for neuropathic pain, and
pregabalin an NNT of 7.7 [14]. Gabapentin and pregabalin
both have no clinically important drug–drug interactions.
Gabapentin dose titration may take several weeks, whereas
the starting dose of pregabalin of 75 mg twice daily is
already efficacious [15]. The potential for twice-daily
dosing and the linear pharmacokinetics leading to a pre-
dictable dose–response relationship of pregabalin may be
an advantage in the ease of use of this drug.
Side effects of gabapentin and pregabalin are somno-
lence, dizziness, ataxia, edema and tremor. Pregabalin
increases slow wave sleep and total sleep duration in
patients with pain [69], and can also be used for general-
ized anxiety disorders. Both drugs require dosage reduction
in patients with renal impairment [70].
4.2.2 Other Antiepileptic Drugs
Several other antiepileptic drugs, such as topiramate, zon-
isamide, and oxcarbazepine or carbamazepine, have been
studied for neuropathic pain, though most studies were
negative [14], and therefore these drugs are not recom-
mended as first-line treatment.
4.2.3 Anticonvulsants and the Elderly
Gabapentin or pregabalin are usually well tolerated if
titrated appropriately. Treatment should start with the
lowest possible dose and be increased very slowly on the
basis of response and side effects, such as somnolence,
dizziness, ataxia and peripheral edema [71]. Gabapentin
can cause or exacerbate cognitive or gait impairment. Dose
reduction in patients with renal dysfunction is needed [70].
Furthermore, antiepileptic drugs may lead to an increased
risk of falling [71].
4.3 Opioids
Opioids refer to all substances that produce morphine-like
effects that are blocked by antagonists such as naloxone,
and can be produced synthetically or endogenously. Opi-
oids have a well defined role in the treatment of cancer
pain; however, their role in the long-term treatment of non-
malignant pain is controversial because of concerns about
tolerability, the development of tolerance to the analgesic
effect, and addiction [72]. Furthermore, side effects
occurred in about 50 % of patients treated for chronic non-
malignant pain, and more than 20 % discontinued treat-
ment because of adverse events [73, 74]. Opioids can be
effective in neuropathic pain, with an NNT of 4.7 for tra-
madol and 4.3 for strong opioids [14, 75], and are con-
sidered second- and third-line treatments [12, 14, 15].
Opioids produce analgesia by acting on opioid receptors
in peripheral afferent neurons, dorsal horn of the spinal
cord, brainstem and the brain. The opioid receptors are
G protein-coupled receptors and are classified as mu
(MOP), delta (DOP) and kappa (KOP) and a fourth non-
classical opioid receptor for nociceptin/orphanin FQ (NOP)
[76, 77]. The receptor pharmacology is complex; the cel-
lular response does not only depend on the ligand and the
type of receptor, but also on the cellular environment of the
receptor [78, 79]. After activation of the receptor, a portion
of the G protein is released, and leads to inhibition of
cyclic adenosine monophosphate (AMP), with consequent
alteration of protein phosphorylation. Cyclic AMP acts as a
second messenger within the cell, resulting in the activa-
tion of protein kinases (short-term effects) and gene tran-
scription proteins and/or gene transcription (long-term
effects) [80]. Opioid receptors located on the presynaptic
terminals of the nociceptive C- and A-fibers can be acti-
vated by an opioid agonist, which will indirectly inhibit
voltage-gated calcium channels, decreasing cyclic AMP
levels and blocking the release of pain neurotransmitters
such as glutamate, substance P, and calcitonin gene-related
peptide [80]. Furthermore, opioids activate presynaptic
receptors on GABA neurons, which inhibit the release of
GABA in the ventral tegmental area, indirectly leading to
an increase in dopamine. The latter plays a role in the
development of addiction.
One of the most common side effects is constipation,
which requires prophylaxis [72]. Other side effects are
pruritus, dizziness, nausea and vomiting, sedation,
impaired concentration, and ataxia. The risk of respiratory
depression should be weighed in patients with an under-
lying pulmonary condition or receiving concomitant cen-
tral nervous system drugs associated with hypoventilation.
Not all opioids show equal effects on respiratory depres-
sion. Long-term use of opioids can lead to hypogonadism
and immunological changes. Prolonged opioid use may
lead to tolerance (the need to increase the dose to maintain
pain relief) and opioid-induced hyperalgesia [81, 82].
Rotation from one strong opioid to another can restore not
only analgesia, but also cause other side effects [83, 84].
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One of the biggest concerns is addiction due to pro-
longed opioid use, with high health and economic costs and
potentially fatal consequences [85, 86].
Increasing opioid doses are strongly related to large
increases in risk of overdose morbidity and mortality,
with a substantially increased risk associated with doses
at or above 100–120 mg morphine-equivalent dose per
day [86]. Moreover, disordered breathing during non-
REM sleep increases with dose. Therefore, opioid ther-
apy should be part of a multifaceted approach to pain
management [86], and clinicians should be alert for
behavior suggestive of addiction, such as frequent
change of doctors, non-compliance, and reports of lost
prescriptions [85].
4.3.1 Weak Opioids
4.3.1.1 Tramadol Tramadol, a second-line treatment, is a
weak opioid receptor agonist and a norepinephrine and
serotonin (5-HT)-reuptake inhibitor, and has an NNT of 4.7
[14]. Special precautions should be taken with patients with
asthma, epilepsy, and severe liver and renal impairment. It
has interactions with most antidepressant drugs.
4.3.2 Strong Opioids
Strong opioids are considered third-line treatment, and
have an NNT of 4.3 [14].
4.3.2.1 Transdermal Buprenorphine Buprenorphine is a
semisynthetic non-selective mixed opioid agonist–antago-
nist and can bind to the three classical and the non-classical
opioid receptors. The anti-nociceptive effect is primarily
exerted via the mu-receptor and is attenuated by the
nociception receptor. No specific adjustments have to be
made in kidney impairment. Excretion is mainly by the
liver, and liver impairment can prolong the half-life,
however, without clinical relevance, because of low-ac-
tivity metabolites. Precautions should be taken in patients
with asthma or chronic obstructive pulmonary disease
(COPD). When rotating from a pure agonist, withdrawal
symptoms can occur because Buprenorphine is a partial
mu-agonist [87].
4.3.2.2 Oxycodone Sustained-Release Oxycodone is an
agonist for the mu- and kappa-receptor. Oxycodone has
similar efficacy to morphine and is usually well tolerated. It
frequently causes constipation. Oxycodone has multiple
active metabolites that may accumulate in renal dysfunc-
tion [87].
4.3.2.3 Fentanyl Patch Fentanyl is an opioid agonist.
The vast majority of the metabolites—around 75 %—are
eliminated in the urine. In cases of renal impairment, the
clearance of fentanyl is reduced and the terminal half-life
of the drug is prolonged. The clinical significance of this is
not known [87]. In liver impairment, adjustment of dose
may be required, though no specific guideline is available.
Table 1 Practical tips for the best treatment strategy for small fiber neuropathy in the elderly
Practical tips for the clinician
Always make the best choice considering safety and tolerability, strive for tailor-made therapy and individualization of care in clinical practice
Local treatment In case of focal pain distribution or systemic contra-indications
Medication Take a careful medication history
Ask for previous adverse effects, inadequate effects, inadequate dose
Check for comorbidity such as liver and kidney impairment
Check potential interactions with other drugs, herbs, caffeine, smoking, grapefruit
Adjust dose if necessary
Consider genetic testing in patients with a history of many side effects
Make patient also responsible for medication history by handing out a form for medication
Opioids Avoid instant-release opioids
Start strong opioids only as third-line treatment
Be aware of the potential risks
Social context Ask for impact on sleep, work, daily functioning, relationship, and anxiety, and treat when possible
Age Avoid polypharmacy as much as possible
Strive for treatment with the least side effects
Always start low, go slow!
AND if nothing works consider multi-targeting!
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4.3.2.4 Methadone Methadone is a synthetic opioid (mu
agonist), a weak NMDA receptor antagonist and a sero-
tonin-reuptake inhibitor. No adjustments have to be made
in kidney impairment. In serious liver failure, the use of
methadone is contraindicated. Methadone can have a long
and variable half-life time. Variation of half-life is 8–80 h,
with a risk of accumulation. It has potential interactions
with multiple drugs. Furthermore, it may cause prolonga-
tion of the QT-time interval [88], and ECG screening or
monitoring may be considered.
4.3.3 Opioids and the Elderly
Although older people tend to require lower doses than
younger individuals, opioid effects do not appear to vary
with age [89]. Though short-term efficacy of opioid use
(B12 weeks) among older adults has been established,
almost half of the patients discontinued the medication,
mostly because of intolerable side effects [90]. There is
limited evidence in support of long-term opioid treatment
[86, 91]. In the elderly, the half-life time of the active drug
and its metabolites is increased, but not in buprenorphine,
making it a relative safe choice in the elderly [87]. Fur-
thermore, buprenorphine does not have a dose-dependent
decrease in respiration [92, 93]. In elderly patients with
impaired hepatic and renal function, there is the risk of
accumulation of metabolites from certain opioids, such as
morphine.
Given the established risks associated with opioid use,
such as hospital admission, mortality and fractures [94], the
potential negative effects must be carefully weighed and be
used as part of an integrated treatment program, including
functional and psychosocial modalities [87, 94]. Metha-
done should only be prescribed by clinicians who have
considerable experience with the drug, or in closely mon-
itored settings, because of difficulty in titration [62].
Fig. 2 Treatment algorithm for SFN in the elderly. In addition to
physical factors, psychological, neurophysiological, socio-economic
and cultural aspects may influence the experience and maintain pain;
a multidisciplinary approach in line with the biopsychosocial model is
required in optimizing treatment for the individual patient [41].
Asterisks see also Fig. 3 (contra-indication algorithm for drugs
prescription) and Table 1 (Practical tips for the best treatment
strategy for SFN in the elderly). Hash in contrast with first-line
neuropathic pain treatment in adults \65 years, TCAs should be
avoided in older adults, because of the risk of adverse events, such as
cardiac arrhythmia, somnolence, hypotension with increased risk of
falls and injury, cognitive impairment, and anticholinergic side effects
[62]. SFN small fiber neuropathy, SNRI serotonin-noradrenalin
reuptake inhibitor, TCA tricyclic antidepressant
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4.4 Topical Analgesic Agents
Topical administration may be better tolerated than other
routes of administration. However, the efficacy of topical
lidocaine and capsaicin in the management of localized
neuropathic pain is limited, and therefore these drugs are
considered second-line treatment [14, 41].
4.4.1 Capsaicin
Capsaicin is the primary component in hot peppers that
gives the highly strong spicy flavor. Topical capsaicin is
available in cream with low-concentration capsaicin
(0.025–0.075 %) and transdermal patches with high-con-
centration capsaicin (8 %). Capsaicin can only be used
when the skin is intact and has no interaction with other
medication. There are minimal systemic side effects (hy-
pertension, first-degree atrioventricular block, coughing,
nausea). Local side effects are erythema, burning pain and
itch. Topical treatment with capsaicin can cause reversible
degeneration of epidermal nerve fibers. The long-term
safety of repeated applications of high-concentration cap-
saicin patches, particularly with respect to this epidermal
nerve fiber degeneration, is unknown [14].
4.4.2 Lidocaine 5 % Medicated Plaster
Topical lidocaine has been used for both acute and chronic
pain treatments. The effect of the lidocaine plaster is based
on two actions. The plaster itself provides a cooling per-
ception and mechanical protection [95–97]. Additionally,
lidocaine is a VGSC inhibitor, which stabilizes the neu-
ronal membrane potential of Ad- and C-fibers. This phar-
macological action results in a reduction of pain and
allodynia [98]. The 5 % lidocaine-medicated plaster has
minimal systemic absorption of the active substance [99],
with a low risk of toxicity and a lack of drug–drug inter-
actions [100]. Although the absorption of the skin is
extremely low, caution is needed in patients with class 1
antiarrhythmic drugs or other local anesthetics.
4.4.3 Topical Agents and the Elderly
Lidocaine patch and high-concentration capsaicin patches
are considered second-line treatment because of low effect
sizes. However, lidocaine patches may be considered as a
first-line drug in case of side effects or safety of other first-
line treatments, particularly in elderly patients [14].
5 Complementary Therapies
5.1 Transcutaneous Electrical Nerve Stimulation
TENS is the application of electrical stimulation of varying
frequency, intensity and pulse duration to the skin for pain
relief [101]. TENS is generally believed to be a safe non-
invasive intervention. However, the effectiveness of TENS
in chronic pain has not been established with certainty [43].
5.2 TENS and the Elderly
Age does not have a significant impact on pain or TENS
comfort, though age-related changes might limit the use of
TENS among the older population [41, 102].
6 Multifaceted Neuropathic Pain Management
in the Elderly
Managing neuropathic pain in the elderly is often complex
because of its multifactorial facets. The neurobiology of
aging, its relation to pain, changes in pharmacokinetics,
drug metabolism, and body composition, polypharmacy
and cognitive and affective factors may influence pain
expression and pain management in the elderly [103].
Individual drugs have 50 % of pain relief, with an NNT
of 4–10, meaning that the outcome of drug treatment is, at
best, moderate [14, 104]. Multifaceted therapy is often
needed to address the various pain conditions, whereas
older people may be particularly susceptible to side effects
and drug interactions. A practical approach is presented in
Table 1 and Figs. 2 and 3.
In general, medication should be started in a low dose
and titrated slowly. TCAs should be avoided in the elderly
if possible, or at least not be prescribed above 75 mg/day.
A therapeutic trial should be of adequate length to assess
efficacy, and the dose needs to be adjusted if side effects
become burdensome, with a slower titration curve to attain
therapeutic levels if needed [62, 103]. It is important to
optimize one regimen first, and then gradually add agents,
if needed. Therapies which have overlapping pharmaco-
dynamics or that may have an adverse pharmacokinetic
interaction, such as metabolic inhibitors, should not be
combined. Especially in older patients, attention is needed
regarding agents acting within the central nervous system.
Therapy should be tapered down over time, if possible, to
attain the lowest effective maintenance dose.
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7 Discussion and Future Perspectives
In general, the treatment of chronic neuropathic pain is
complicated and multidimensional. The mechanisms
underlying its occurrence and chronification, as well as
the inter-individual variability, remain poorly understood.
As a consequence, symptomatic and unspecific treatments
are frequently the only available therapeutic options.
Indeed, all the clinical trials carried out in the last
20 years provided similar results, accounting for 50 % of
pain relief in 50 % of patients at best [12, 14]. Effica-
cious and tailored treatments for neuropathic pain are the
ultimate target both for patients and scientists. The dis-
covery of gain-of-function NaV1.7, NaV1.8 and NaV1.9
mutations in painful peripheral neuropathy has expanded
the spectrum of painful sodium channelopathies [6, 34]. It
provides a better understanding of the pathogenetic
mechanisms and may provide targets for potential
treatment with the expectation of fewer side effects
[105–107]. Genetics may also play a role in drug
response. For some drugs, pharmacogenetics can predict
the efficacy and toxicity of treatment at the individual
level [108–110].
As pain is a complex symptom, inwhich not only physical
factors but also psychological, neurophysiological, socio-
economic and cultural aspects may influence the experience
and continuation of pain, amultidisciplinary approach in line
with the biopsychosocial model is required in optimizing
treatment for the individual patient (Fig. 2) [41]. Psycho-
logical techniques may be helpful, not just when pharma-
cological therapy is ineffective, but as an adjunct to
medication or as a first-line therapy if the patient prefers.
Moreover, chronic pain often has coexisting symptoms, such
as depression, anxiety and sleep deprivation, and focusing on
relief of these symptoms may be crucial for patients.
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